U.S. Full Prescribing Information Including BOXED WARNINGS

Medication Guide

Healthcare Professionals Site

En Español

Indications

This site is intended for U.S. residents 18 years of age or older.

  • Adult Nonvalvular AFib

    ELIQUIS (apixaban) is a prescription
    medicine used in adults to reduce the risk of stroke and blood clots in people who have atrial fibrillation (AFib), a type of irregular heartbeat, not caused by a heart valve problem.

  • Adult DVT/PE

    ELIQUIS (apixaban) is a prescription
    medicine used in adults to treat blood clots in the veins of your legs (deep vein thrombosis-DVT) or lungs (pulmonary embolism-PE), and to reduce the risk of them occurring again after receiving treatment for blood clots.

  • Pediatric DVT/PE

    ELIQUIS (apixaban) is a prescription
    medicine used in children from birth and older to treat blood clots in the veins of legs and lungs (venous thromboembolism) after at least 5 days of initial anticoagulant treatment, and to reduce the risk of them happening again. ELIQUIS was not studied and is not recommended in children weighing less than 5.7 pounds (2.6 kg).

  • Adult Hip/Knee Replacement

    ELIQUIS (apixaban) is a prescription
    medicine used in adults to help prevent a blood clot in the veins of your legs (deep vein thrombosis-DVT) and lungs (pulmonary embolism-PE) of people who have just had hip or knee replacement surgery.

For adult patients

Or Call Us at 1-855-ELIQUIS (354-7847)

Sign up for ELIQUIS 360 Support

U.S. Full Prescribing Information Including BOXED WARNINGS

Indications

  • Adult Nonvalvular AFib

    ELIQUIS (apixaban) is a prescription
    medicine used in adults to reduce the risk of stroke and blood clots in people who have atrial fibrillation (AFib), a type of irregular heartbeat, not caused by a heart valve problem.

  • Adult DVT/PE

    ELIQUIS (apixaban) is a prescription
    medicine used in adults to treat blood clots in the veins of your legs (deep vein thrombosis-DVT) or lungs (pulmonary embolism-PE), and to reduce the risk of them occurring again after receiving treatment for blood clots.

  • Pediatric DVT/PE

    ELIQUIS (apixaban) is a prescription
    medicine used in children from birth and older to treat blood clots in the veins of legs and lungs (venous thromboembolism) after at least 5 days of initial anticoagulant treatment, and to reduce the risk of them happening again. ELIQUIS was not studied and is not recommended in children weighing less than 5.7 pounds (2.6 kg).

  • Adult Hip/Knee Replacement

    ELIQUIS (apixaban) is a prescription
    medicine used in adults to help prevent a blood clot in the veins of your legs (deep vein thrombosis-DVT) and lungs (pulmonary embolism-PE) of people who have just had hip or knee replacement surgery.

Medication Guide

Or Call Us at 1-855-ELIQUIS (354-7847)

Sign up for ELIQUIS 360 Support

Healthcare Professionals Site

En Español

CO-PAY CARD ELIGIBILITY REQUIREMENTS:

FREE TRIAL OFFER ELIGIBILITY REQUIREMENTS:

You may be eligible for the Co-pay Card for
ELIQUIS® (apixaban) if:

  1. You are insured by commercial insurance and your prescription insurance coverage does not cover the full cost of your prescription, that is, you have a co-pay obligation for ELIQUIS;
  2. You do not have prescription insurance coverage through a state or federal healthcare program, including but not limited to Medicare Part D, Medicaid, Medigap, CHAMPUS, TRICARE, Veterans Affairs (VA), or Department of Defense (DOD) programs; patients who move from commercial plans to state or federal healthcare programs will no longer be eligible;
  3. You are a resident of the United States, Puerto Rico, or other select U.S. Territory.

TERMS OF USE:

  1. Eligible patients who present an activated Co-pay Card together with a valid prescription for ELIQUIS at participating pharmacies may pay as little as $10 for a 30-day supply or $10 for their first 90-day supply of ELIQUIS. Patients may pay as little as $30 for subsequent 90-day refills. Program is subject to a maximum annual benefit of $3,500. Program benefit subject to continued eligibility. Patients are evaluated for ongoing eligibility. If insurance changes or Bristol Myers Squibb changes the co-pay assistance program, patients may be required to re-enroll and provide updated insurance information. Other restrictions may apply. Patient is responsible for applicable taxes, if any.
  2. Offer not applicable to co-pays of $10 or less.
  3. Patients, pharmacists, and prescribers cannot seek reimbursement from health insurance or any third party, for any part of the benefit received by the patient through this offer.
  4. Your acceptance of this offer confirms that this offer is consistent with your insurance and that you will report the value received as may be required by your insurance provider.
  5. This card is valid only while the Co-Pay Card Program is active and is subject to the current Terms of Use listed on this page.
  6. All Program payments are for the benefit of the patient only.
  7. Only valid in the United States, Puerto Rico, and other select U.S. Territories; this offer is void where restricted or prohibited by law.
  8. This offer is non-transferable, no substitutions are permissible, and offer cannot be combined with any other rebate/coupon, free trial, or similar offer for the specified prescription.
  9. The Co-pay Card may not be sold, purchased, traded, or counterfeited. Reproductions of this Co-pay Card are void.
  10. Bristol Myers Squibb and Pfizer reserve the right to rescind, revoke, or amend this offer at any time without notice.
  11. This offer is not conditioned on any past, present, or future purchase, including refills.
  12. No membership fees.
  13. The Co-pay Card for ELIQUIS is not health insurance.

    The Co-pay Card will be accepted only at participating pharmacies. For those customers using mail order or any non-participating retail pharmacy, please call 866-279-4730 to request a patient rebate form, or go to www.patientrebateonline.com to download a form.

Questions can also be submitted via mail to:

P.O. Box 2914
Phoenix, AZ, 85062-2914.

By using this card, you and your pharmacist agree to review and comply with the eligibility requirements and the most current Terms of Use listed on this page. In the event of any conflict between the Terms of Use on the card and the online Terms of Use, the online Terms of Use will govern.

To the pharmacist: For processing assistance, please call McKesson Pharmacy Support at 1-866-279-4730

Please see Full Prescribing Information, including Boxed WARNINGS and Medication Guide.

FREE TRIAL OFFER ELIGIBILITY REQUIREMENTS:

You may be eligible for the Free 30-Day Trial Offer for ELIQUIS® (apixaban) if:

  1. You have not previously filled a prescription for ELIQUIS;
  2. You have a valid 30-day prescription for ELIQUIS;
  3. You are being treated with ELIQUIS for an FDA-approved indication that an HCP has planned for more than 35 days of treatment;
  4. You are a resident of the United States, Puerto Rico, or other select U.S. Territory.

TERMS OF USE:

  1. Eligible patients who present a Free 30-Day Trial card together with a valid 30-day prescription for ELIQUIS at participating pharmacies can receive a free 30-day supply (up to 74 tablets) of ELIQUIS. Patient is responsible for applicable taxes, if any. This offer may not be redeemed on prescriptions written for longer than 30 days.
  2. This offer is limited to one use per patient per lifetime and is non-transferable. By redeeming this offer, you certify that you have not previously filled a prescription for ELIQUIS.
  3. The Free 30-Day Trial for the specified prescription cannot be combined with any other rebate/coupon, free trial, or similar offer. No substitutions are permitted.
  4. Patients, pharmacists, and prescribers cannot seek reimbursement for the Free 30-Day Trial of ELIQUIS from health insurance or any third party, including state or federally funded programs.
  5. Patients may not count the Free 30-Day Trial of ELIQUIS as an expense incurred for purposes of determining out-of-pocket costs for any plan, including true out-of-pocket costs, (TrOOP), for purposes of calculating the out-of-pocket threshold for Medicare Part D plans.
  6. This card is valid only while the Co-Pay Card Program is active and is subject to the current Terms of Use listed on this page.
  7. Only valid in the United States, Puerto Rico, and other select U.S. Territories; this offer is void where restricted or prohibited by law.
  8. Bristol-Myers Squibb and Pfizer reserve the right to rescind, revoke, or amend this offer at any time without notice.
  9. This Free 30-Day Trial card may not be sold, purchased, traded, or counterfeited. Reproductions of this card are void.
  10. This offer is not conditioned on any past, present, or future purchase, including refills.
  11. The ELIQUIS Free 30-Day Trial offer is not health insurance.

By using this card, you and your pharmacist agree to review and comply with the eligibility requirements and the most current Terms of Use listed on this page. In the event of any conflict between the Terms of Use on this card and the online Terms of Use, the online Terms of Use will govern.

To the pharmacist: For processing assistance, please call McKesson Pharmacy Support at 1-866-279-4730.

Please see Full Prescribing Information, including Boxed WARNINGS and Medication Guide.

432-US-2600331 09/26

Important facts about ELIQUIS® (apixaban) tablets and ELIQUIS® SPRINKLE (apixaban)

 

This is a summary of important safety information that you need to know about ELIQUIS. Keep this document in a safe place, so you can refer to it before and during your treatment.

Look out for the following icons as you read:

Talk to your
healthcare team

Call a healthcare
provider right away

Helpful information
to remember

What is the most important information I should know about ELIQUIS?

ELIQUIS may cause serious side effects, including:

Increased risk of blood clots if you stop taking ELIQUIS

ELIQUIS lowers your chance of having a stroke by helping to prevent clots from forming. If you stop taking ELIQUIS, you may have an increased risk of a clot forming in your blood.

Do not stop taking ELIQUIS without talking to the healthcare provider who prescribed it to you.

Stopping ELIQUIS increases your risk of having a stroke.

Talk to your healthcare team before any medical procedures. ELIQUIS may need to be stopped before surgery or a medical or dental procedure. Your healthcare provider will tell you when you should stop taking ELIQUIS and when you may start taking it again. If you have to stop taking ELIQUIS, your healthcare provider may prescribe another medicine to help prevent a blood clot from forming.

Bleeding

ELIQUIS can cause bleeding, which can be serious, and may lead to death. This is because ELIQUIS is a blood thinner medicine that reduces blood clotting. While taking ELIQUIS, you may bruise more easily and it may take longer than usual for any bleeding to stop.

You may have a higher risk of bleeding if you take ELIQUIS and take other medicines that increase your risk of bleeding, such as:

  • Aspirin or aspirin-containing products

  • Long-term (chronic) nonsteroidal anti-inflammatory drugs (called NSAIDs)

  • Warfarin sodium

  • Any medicine that contains heparin

  • Clopidogrel

  • Selective serotonin reuptake inhibitors (SSRIs) or serotonin norepinephrine reuptake inhibitors (SNRIs)

  • Other medicines to help prevent or treat blood clots

Tell your healthcare provider if you take any of these medicines.

Call your healthcare provider or get medical help right away if you or your child have any of these signs or symptoms of bleeding when taking ELIQUIS:

  • Unexpected bleeding or bruising or bleeding that lasts a long time, such as:

    • Unusual bleeding from the gums

    • Nosebleeds that happen often

    • Menstrual or vaginal bleeding that is heavier than normal

  • Bleeding that is severe or you cannot control

  • Red, pink, or brown urine

  • Red or black stools (looks like tar)

  • Coughing up or vomiting blood or blood clots

  • Vomit that looks like coffee grounds

  • Unexpected pain, swelling, or joint pain

  • Headaches

  • Feeling dizzy or weak

Spinal or epidural blood clots (hematoma)

People who take a blood thinner medicine like ELIQUIS, and have medicine injected into their spinal or epidural area, or have a spinal puncture, have a risk of forming a blood clot that can cause long-term or permanent loss of the ability to move (paralysis).

Your risk of developing a spinal or epidural blood clot is higher if:

  • A thin tube called an epidural catheter is placed in your back to give you certain medicine

  • You take NSAIDs or a medicine to prevent blood from clotting

  • You have a history of difficult or repeated epidural or spinal punctures

  • You have a history of problems with your spine or have had surgery on your spine

If you take ELIQUIS and receive spinal anesthesia or have a spinal puncture, your healthcare provider should watch you closely for symptoms of spinal or epidural blood clots or bleeding.

Tell your healthcare provider right away if you have any of these signs or symptoms when taking ELIQUIS:

  • Back pain

  • Tingling, numbness, or muscle weakness, especially in your legs and feet

  • Loss of control of the bowels or bladder (incontinence)

Talk to your healthcare provider about any side effect that may be bothering you or that does not go away. These are not all of the possible side effects of ELIQUIS. Call your healthcare provider for medical advice about side effects.

You are encouraged to report any side effects to the FDA at 1-800-FDA-1088.

Who should not take ELIQUIS?

ELIQUIS is not for patients who:

  • have artificial heart valves

  • have antiphospholipid syndrome (APS), especially with positive triple antibody testing

  • currently have certain types of abnormal bleeding

  • have had a severe allergic reaction to ELIQUIS or any of the ingredients

What should I discuss with my healthcare team before starting ELIQUIS?

Talk to your healthcare team if you or your child:

  • Have or ever had bleeding problems

  • Have kidney or liver problems

  • Have antiphospholipid syndrome (APS)

  • Are pregnant or plan to become pregnant. It is not known if ELIQUIS will harm your unborn baby

Tell your healthcare provider right away if you become pregnant during treatment with ELIQUIS. Taking ELIQUIS during pregnancy may increase the risk of bleeding in you or your unborn baby.

Females who are able to become pregnant: talk with your healthcare provider about pregnancy planning, and your risk of severe uterine bleeding if you are treated with ELIQUIS.

Tell your healthcare provider if you are breastfeeding or plan to breastfeed. It is not known if ELIQUIS passes into your breast milk. Do not breastfeed during treatment with ELIQUIS. Talk to your healthcare provider about the best way to feed your baby during treatment with ELIQUIS.

Tell your healthcare team about all the medicines you or your child take, including any:

  • prescription medicines

  • over-the-counter medicines

  • vitamins

  • herbal supplements

During treatment, make sure you talk to your healthcare team before you begin to take any new medication.

What are the possible serious side effects of ELIQUIS?

The most common side effect of ELIQUIS in adults was bleeding.

The most common side effects of ELIQUIS in children include: headache, vomiting, heavy menstrual bleeding.

How should I take ELIQUIS?

Take ELIQUIS exactly as prescribed by your healthcare provider.

  • Twice daily

Do not change your dose or stop taking ELIQUIS unless your healthcare provider tells you to.

What if I miss a dose of ELIQUIS?

If you or your child misses a dose of ELIQUIS, take it as soon as you remember on the same day. Do not take two doses of ELIQUIS at the same time to make up for a missed dose. Return to your usual dosing schedule the next day.

For children who take ELIQUIS:

  • See the detailed Instructions for Use that comes with ELIQUIS SPRINKLE for oral suspension or ELIQUIS tablets for oral suspension for information on how to prepare and give a dose of ELIQUIS to children who weigh less than 77 pounds (35 kg).

  • Always give ELIQUIS exactly as your child’s healthcare provider or pharmacist has told you.

  • The dose of ELIQUIS is based on your child’s body weight. Your child’s healthcare provider may need to change your child’s dose as their weight changes. Do not change your child’s dose without talking with the healthcare provider.

  • If your child vomits or spits up within 30 minutes after taking ELIQUIS, repeat the dose. If your child vomits or spits up more than 30 minutes after taking ELIQUIS, do not repeat the dose. Continue to give the next ELIQUIS dose at the next scheduled time.

  • Contact the healthcare provider if your child repeatedly vomits or spits up after taking ELIQUIS.

When should I refill my prescription?

Do not stop taking ELIQUIS without first talking with your healthcare provider. Do not run out of ELIQUIS. Refill your prescription before you run out. When leaving the hospital following hip or knee replacement, be sure that you will have ELIQUIS available to avoid missing any doses.

ELIQUIS is available in two different tablets. Your healthcare provider will determine what dose is right for you.

2.5 mg tablet

Yellow, round

OR

5 mg tablet

Pink, oval

On one side of each film-coated tablet, there is a number indicating the dosage strength of the tablet (in milligrams). On the other side, there is a medication identification number.

ELIQUIS is also available as ELIQUIS SPRINKLE, a capsule containing a powder for oral suspension, or as a film-coated tablet for oral suspension for pediatric patients.

0.15 mg capsule

Yellow, opaque

OR

0.5 mg tablet

Pink, round

Note: Images do not represent actual tablet or capsule size.

The capsule is printed with a medication identification number.

What is ELIQUIS?

ELIQUIS is a prescription medicine used in adults to:

Reduce the risk of stroke and blood clots in people who have atrial fibrillation (AFib), a type of irregular heartbeat, not caused by a heart valve problem.

Treat blood clots in the veins of the legs (deep vein thrombosis – DVT) or lungs (pulmonary embolism – PE), and reduce the risk of them occurring again after receiving treatment for blood clots.

Help prevent a blood clot in the legs (DVT) and lungs (PE) of people who have just had hip or knee replacement surgery.

ELIQUIS is a prescription medicine used in children from birth and older to:

Treat blood clots in the veins of the legs and lungs (venous thromboembolism) after at least 5 days of initial coagulant treatment, and reduce the risk of them occurring again.

ELIQUIS was not studied and is not recommended in children who weigh less than 5.7 pounds (2.6 kg).

Please see U.S. Full Prescribing Information, including Boxed WARNINGS and Medication Guide.

The product information provided in this site is intended only for residents of the United States. The products discussed herein may have different product labeling in different countries.

The health information contained herein is provided for educational purposes only and is not intended to replace discussions with a healthcare provider. All decisions regarding patient care must be made with a healthcare provider, considering the unique characteristics of the patient.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch, or call 1-800-FDA-1088.